Heidelberg Pharma AG (HPHA.DE)
XETRA - XETRA Delayed price. Currency in EUR
Add to watchlist
As of 04:31PM CEST. Market open.
| Previous close | 2.9700 |
| Open | 2.9500 |
| Bid | 2.9500 x N/A |
| Ask | 2.9800 x N/A |
| Day's range | 2.9500 - 2.9800 |
| 52-week range | 2.6300 - 4.0700 |
| Volume | |
| Avg. volume | 8,877 |
| Market cap | 138.883M |
| Beta (5Y monthly) | -0.30 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4000 |
| Earnings date | 11 July 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.Heidelberg Pharma First Quarter 2024 Earnings: €0.10 loss per share (vs €0.14 loss in 1Q 2023)
Heidelberg Pharma ( ETR:HPHA ) First Quarter 2024 Results Key Financial Results Revenue: €1.86m (down 10% from 1Q...
PR NewswireRedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the first patient has been enrolled in the Austere environments Consortium for Enhanced Sepsis Outcomes' (ACESO) U.S. government-supported PROTECT multinational platform trial for early COVID-19 outpatient treatment. RHB-107 (upamostat) is the first drug being tested in this platform study. Funded through non-dilutive external sources, including the U.S. Department of D
Simply Wall St.Shareholders in Heidelberg Pharma (ETR:HPHA) are in the red if they invested three years ago
The truth is that if you invest for long enough, you're going to end up with some losing stocks. But long term...
© 2024 Yahoo. All rights reserved.